Challenge 1: Data lives everywhere except where you need it

Ask any lab manager where their experimental data actually lives and you will get a complicated answer. Some of it is in an ELN. Some is in shared drives. A fair amount is trapped in instrument-specific software that nobody else on the team can access. And then there are the spreadsheets — dozens of them, each maintained by a different person with a different naming convention.

This fragmentation is not just annoying. It creates real problems when you need to pull data for a partner meeting, an investor presentation, or — worst case — a regulatory submission. Teams end up spending hours reconstructing timelines and chasing down records that should have been centralized from the start.

How leading teams are solving it

The labs that have moved past this problem did one thing first: they picked a single platform to serve as the source of truth for experimental and sample data. That does not mean abandoning every other tool — it means choosing a hub that everything connects to. A modern LIMS like Genemod serves this role well because it integrates sample tracking, experiment records, and protocol management into one place. When a new team member joins, they do not have to learn six different systems. They learn one.

Challenge 2: Regulatory requirements are getting harder to ignore

Two years ago, a seed-stage biotech could get away with informal documentation practices. That window is closing fast. The FDA's focus on data integrity in preclinical and clinical submissions has trickled down to earlier-stage companies. Partners and acquirers are asking to see audit trails during diligence. And if you are working in cell and gene therapy, the documentation requirements for chain-of-custody and environmental monitoring are significant even at the development stage.

The challenge is not that labs do not care about compliance — it is that building GMP-ready documentation practices is time-consuming and expensive when your primary focus is moving the science forward.

How leading teams are solving it

Smart teams are baking compliance into their daily workflows instead of treating it as a separate workstream. That means using an ELN that automatically timestamps entries, prevents backdating, and creates immutable audit trails. It means tracking samples with full chain-of-custody records from the moment they arrive in the lab. And it means choosing software that is designed with regulatory frameworks in mind, so the documentation is already structured the way an auditor expects to see it.

Challenge 3: Scaling operations without scaling headcount proportionally

Hiring is still one of the hardest problems in biotech. Experienced scientists are in high demand, and startups compete for talent against well-funded pharma companies that can offer higher salaries and better benefits. The result is that most labs are trying to increase throughput and complexity with teams that are the same size — or smaller — than they were a year ago.

When you cannot solve a problem by adding people, you have to solve it with better systems. Labs that are stuck on manual processes — tracking inventory by hand, copying data between systems, scheduling experiments over email — hit a ceiling fast.

How leading teams are solving it

The most operationally efficient labs in 2026 have automated or streamlined the tasks that do not require scientific judgment. Inventory alerts that fire when reagents drop below threshold. Protocol templates that auto-populate standard fields. Sample tracking that updates in real time without anyone manually entering a freezer location. These are not revolutionary innovations — they are basic operational hygiene — but the cumulative time savings are substantial. One lab manager described it as getting back ten hours a week across the team, which translates directly into more experiments per quarter.

Challenge 4: Onboarding new team members takes too long

A recurring frustration for growing labs is how long it takes to bring a new scientist up to speed. This is not just about learning the science — it is about learning the systems. Where are the protocols stored? How do I log an experiment? Which freezer has my samples? Who do I ask when something breaks?

When your lab runs on a patchwork of tools and tribal knowledge, onboarding takes weeks. And during those weeks, the new hire is not only unproductive — they are also pulling time away from senior team members who have to walk them through everything.

How leading teams are solving it

Labs with centralized platforms report dramatically faster onboarding. When everything — protocols, inventory, notebooks, ordering — lives in one system, the learning curve flattens. New hires can follow existing templates, browse previous experiments for context, and find what they need without asking five different people. One biotech CTO mentioned that switching to Genemod cut their average onboarding time from three weeks to five days for lab-facing roles.

Challenge 5: Making decisions with incomplete or outdated data

Speed matters in biotech. The difference between advancing a program on time and missing a milestone often comes down to how quickly the team can make informed decisions. But decision-making suffers when the data is scattered, stale, or inconsistent.

Lab directors frequently describe situations where critical decisions — which compound to advance, whether to repeat an experiment, how to allocate limited samples — are made based on incomplete information because pulling together the full picture would take too long.

How leading teams are solving it

The fix is straightforward in principle: make data accessible and current. In practice, that requires a system where experimental results, sample status, and resource availability are all visible from one dashboard. Labs that achieve this can run weekly pipeline reviews in thirty minutes instead of spending half a day just gathering the data. The leadership team sees the same numbers the bench scientists see, which eliminates the telephone-game effect that plagues labs with fragmented systems.

The common denominator

Every challenge on this list traces back to the same root cause: the tools and systems that biotech labs rely on were not built for how modern teams actually work. Legacy LIMS platforms were designed for large pharma. Consumer-grade tools like spreadsheets and shared drives were never meant to handle scientific data at scale. And ad-hoc solutions stitched together over time create fragility that gets worse as the team grows.

The labs that are thriving in 2026 made a deliberate choice to invest in purpose-built infrastructure early. They chose platforms like Genemod that combine LIMS, ELN, and inventory management in a single system designed for biotech-scale operations. And they treat operational excellence not as a nice-to-have, but as a competitive advantage that compounds over time.

If your lab is hitting these walls, the solution is not to work harder. It is to build a better foundation.